IgA nephropathy
IgA nephropathy and the new targeted treatments being studied.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 21, 18, 18, 47, 47.
New guidelines and consensus this year
All papers from the last 12 months
889 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- A self-powered sensor with cascade signal amplification strategy based on CuS@Au heterojunctions/Ti(3)C(2) MXene for detection of IgAN urinary miRNA-23b-3pTalanta2027 Feb 1PMID 42623826
- Multi-omics body-fluid biomarkers in immunoglobulin a nephropathy: Analytical Validation, standardization, and clinical chemistry translation of diagnostic and prognostic AnalytesClin Chim Acta2027 Jan 1PMID 42297320Review
- The shared mechanisms and potential diagnostic markers for IgA nephropathy and celiac diseaseAutoimmunity2026 Dec 31PMID 41714845
- Clinical and pathological factors associated with eGFR slope in IgA nephropathy: a single-center retrospective cohort studyRen Fail2026 DecPMID 42844235
- Artificial intelligence-powered renal pathology for glomerular disease classification: a systematic review and meta-analysisRen Fail2026 DecPMID 42838512Meta-analysisSystematic review
- Microplastics and IgA nephropathy: a novel environmental hypothesis of immune dysregulationRen Fail2026 DecPMID 42817229Review
- Smoking exposure and long-term progression of IgA nephropathy: a retrospective cohort study of 9,560 patientsRen Fail2026 DecPMID 42786735
- Clinical characteristics and prognosis of IgA nephropathy and comorbid diabetic kidney diseaseAnn Med2026 DecPMID 42714219
- Kidney biopsy in patients with small kidneys: diagnostic yield and treatment modification in a retrospective cohort studyRen Fail2026 DecPMID 42687510
- Efficacy and safety of finerenone in adults with IgA nephropathy: a 12-month real-world studyRen Fail2026 DecPMID 42634326
More nephrology trends
All specialties →GLP-1 drugs in kidney disease
GLP-1 based medicines and kidney outcomes.
Key point: In CKD, GLP-1 receptor agonists were associated with fewer major adverse kidney events and lower albuminuria, primarily in type 2 diabetes, with gastrointestinal concerns.
SGLT2 inhibitors in CKD
SGLT2 inhibitors to slow chronic kidney disease.
Key point: In non-diabetic CKD, renin-angiotensin system inhibitors and SGLT2 inhibitors would be indicated as the treatment of choice.
Acute kidney injury biomarkers
Biomarkers to detect and predict acute kidney injury.
Lupus nephritis
Kidney involvement in lupus and its newer treatments.
Key point: Lupus nephritis management is increasingly individualized, with expanding treatment options, combination therapy, and a trend toward lower corticosteroid doses.
Complement inhibitors in kidney disease
Iptacopan, avacopan and other complement inhibitors in glomerular disease.
Key point: Complement inhibitors had no overall effectiveness or safety advantage over plasma therapy in atypical hemolytic uremic syndrome, except lower relapse rates.
APOL1 kidney disease
Kidney disease linked to APOL1 gene variants.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"IgA nephropathy"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.